Cannabis use and cannabis use disorders

被引：0

作者：

Hoch, E. ^{[1
,2
,3
]}

Preuss, U. W. ^{[4
,5
]}

机构：

[1] Klin Ludwig Maximilians Univ Munchen, Klin & Polyklin Psychiat & Psychotherapie, Nussbaumstr 7, D-80336 Munich, Germany

[2] IFT Inst Therapieforsch, Munich, Germany

[3] Charlotte Fresenius Univ, Munich, Germany

[4] Martin Luther Univ Halle Wittenberg, Univ Klin & Poliklin Psychiat Psychotherapie & Psy, Halle, Germany

[5] Klin Ludwigsburg, Klin Psychiat Psychotherapie & Psychosomat, Ludwigsburg, Germany

来源：

NERVENARZT | 2024年 / 95卷 / 09期

关键词：

Tetrahydrocannabinol; Legalization; Neuronal networks; Mental disorders; S3; guidelines; CENTRAL NEUROPATHIC PAIN; ADVANCED CANCER-PATIENTS; DEFAULT MODE NETWORK; DOUBLE-BLIND; MULTIPLE-SCLEROSIS; PARALLEL-GROUP; OROMUCOSAL SPRAY; RANDOMIZED WITHDRAWAL; MARIJUANA WITHDRAWAL; ADOLESCENT EXPOSURE;

D O I：

10.1007/s00115-024-01722-5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Cannabis use and cannabis use disorders have taken on a new social significance as a result of partial legalization. In 2021 a total of 4.5 million adults (8.8%) in Germany used the drug. The number of users as well as problematic use have risen in the last decade. Cannabis products with a high delta-9-tetrahydrocannabinol (THC) content and their regular use lead to changes in cannabinoid receptor distribution in the brain and to modifications in the structure and functionality of relevant neuronal networks. The consequences of cannabinoid use are particularly in the psychological functioning and can include intoxication, harmful use, dependence with withdrawal symptoms and cannabis-induced mental disorders. Changes in the diagnostics between ICD-10 and ICD-11 are presented. Interdisciplinary S3 guidelines on cannabis-related disorders are currently being developed and will be finalized shortly.

引用

页码：781 / 796

页数：16